Sage Journals: Discover world-class research

Abstract

Human leukocyte antigen allosensitization prior to transplant can increase the risk of early graft loss and prolong waitlist times for intestinal transplant candidates. Desensitization offers a potential therapeutic option to reduce the quantity of preformed antibodies prior to organ allocation and facilitate transplantation with a more immunologically compatible donor allograft. However, there remains a paucity of data to guide the use of desensitization in the setting of intestinal transplantation. As a result, in this review we evaluate the existing literature supporting the role of desensitization therapy in intestinal transplant, describe our own experience with the implementation of a risk-stratified desensitization protocol, and finally explore barriers and unanswered questions that continue to limit the widespread adoption of desensitization as a management strategy for highly sensitized intestinal transplant candidates.

Keywords

immunologic desensitization bortezomib intestinal transplantation graft survival

Get full access to this article

View all access options for this article.

References

Berger

Zeevi

Farmer

Abu-Elmagd

. Immunologic challenges in small bowel transplantation. Am J Transplant. 2012;12(suppl 4):S2–S8. doi:10.1111/j.1600-6143.2012.04332.x.

Gondolesi

Blondeau

Maurette

et al. Pre-transplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. Transplantation. 2006;81(12):1743–1746.

Jordan

Tyan

Stablein

et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15(12):3256–3262.

Garcia-Roca

Tzvetanov

Jeon

Hetterman

Oberholzer

Benedetti

. Successful living donor intestinal transplantation in cross-match positive recipients: initial experience. World J Gastrointest Surg. 2016;8(1):101–105. doi:10.4240/wjgs.v8.i1.101.

Peng

Toyoda

et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89(9):1095–1102. doi:10.1097/TP.0b013e3181d21e7f.

Woodle

Shields

Ejaz

et al. Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant. 2015;15(1):101–108. doi:10.1111/ajt.13050.

Kaneku

Wozniak

Venick

et al. Donor specific HLA antibody desensitization: efficacy and experience at a single intestinal transplant center [abstract]. In: ISBTS 2013 Symposium; 2013 June 26-29; Oxford, England. London, England: The Transplantation Society; 2013. Abstract 30.405.

Kubal

Mangus

Vianna

et al. Impact of positive flow cytometry crossmatch on outcomes of intestinal/multivisceral transplantation: role anti-IL-2 receptor antibody. Transplantation. 2013;95(9):1160–1166. doi:10.1097/TP.0b013e3182888df0.

Nair

Sawinski

Akalin

et al. Effect of high dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant. 2012;26(3):E261–E268. doi:10.1111/j.1399-0012.2012.01657.x.

10.

Abu-Elmagd

Costa

et al. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant. 2012;12(11):3047–3060. doi:10.1111/j.1600-6143.2012.04237.x.

Is There a Role for Desensitization in Intestinal Transplantation?

Abstract

Keywords

Get full access to this article

References